Abstract
Data from experimental model systems and population studies have implicated type I insulin-like growth factor receptor (IGF1R) signaling in many different human cancers. Drugs to disrupt IGF1R function have been developed and are now entering clinical trial. This brief review will identify key areas to consider as these clinical trials move forward.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10123-10127 |
| Number of pages | 5 |
| Journal | Cancer Research |
| Volume | 65 |
| Issue number | 22 |
| DOIs | |
| State | Published - Nov 15 2005 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Type I insulin-like growth factor receptor as a therapeutic target in cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS